Cite
MLA Citation
I. Vergote et al.. “00070 A MULTICENTRE PHASE II TRIAL OF GEFITINIB 500 MG/ DAY IN PATIENTS WITH RECURRENT EGFR-POSITIVE GYNAECOLOGICAL TUMOURS.” International journal of gynecological cancer, vol. 15, n.d., pp. 70–71. http://access.bl.uk/ark:/81055/vdc_100137792998.0x00001c